-
对于恶性肿瘤颈部转移病灶, 采用局部外照射放疗或全身化疗都不能取得良好的疗效, 且患者不良反应较大。手术一般不能彻底切除肿瘤[1]。随着近距离放射治疗技术的发展, 组织间放射性粒子植入治疗颈部转移性恶性肿瘤的方法日益受到重视[2]。本研究对10例肿瘤术后颈部转移患者应用125I粒子行组织间永久性植入, 取得了较好疗效, 现报告如下。
-
10例患者均顺利完成125I粒子植入, 无并发症的发生, 无明显白细胞下降。术后1周复查血液相关指标未见异常, 肝功能和免疫指标较术前无明显变化。11处瘤灶共植入125I粒子260颗, 平均每处24颗, 平均每处释放能量为657.6~756.0 keV。植入后1个月经颈部B超或CT检查, 未见粒子移位。
植入术后颈部转移肿瘤的局部压迫或疼痛均获不同程度改善, 10例患者11处颈部转移肿瘤植入125I粒子1个月后对疼痛程度的治疗效果见表 1。颈部转移性肿瘤病灶疼痛症状完全缓解2处, 部分缓解9处。125I粒子植入治疗1个月后行B超及CT复查, 结果: 11处颈部转移瘤病灶中, 有10处部分缓解, 1处无改变。
0级 1级 2级 3级 植入前 0 0 8 3 植入后 2 9 0 0 表 1 125I粒子植入前后颈部转移瘤灶疼痛程度的变化(病灶数)
10例患者均进行了随访, 其中, 7例肿瘤患者在随访期间存活, 3例患者于术后生存3~8个月。
125I粒子永久性组织间植入治疗颈部转移性恶性肿瘤10例
Ten cases of metastatic cervical cancer with the treatment of permanent 125I seeds interstitial implants
-
摘要:
目的 探讨125I粒子永久性组织间植入治疗颈部转移性恶性肿瘤的临床效果。 方法 在B超引导下将125I粒子植入10例恶性肿瘤切除术后颈部淋巴结转移11处病灶肿瘤组织内,治疗1个月后观察疼痛缓解情况和瘤灶大小等变化并定期随访。 结果 接受125I治疗的10例患者,随访6~14个月,均无不良反应发生。125I粒子植入1个月后,肿瘤病灶疼痛症状完全缓解2处,部分缓解9处;肿瘤病灶体积部分缓解10处,1处无改变。 结论 125I粒子永久性组织间植入治疗颈部转移性恶性肿瘤是一种安全、微创、疗效好的方法。 Abstract:Objective To investigate the clinical effect of permanent 125I seeds interstitial implants for metastatic cervical cancer. Methods Under the guidance of the B-sonography, 125I seeds were implanted into the eleven cervical lymph nodes of ten patients who had been given tumor resection.The pain relief and tumor size were observed in regular follow-up after one-month treatment. Results All the patients were followed up for 6-14 months, and the postoperative recovery was good with no complication.One month after the implantation, the pain symptom was alleviated entirely in two nodes and partly in nine nodes.The tumorsize shrank in ten nodes while there was no change in one node after one month. Conclusion Permanant 125I seeds interstitial implants for metastatic cervical cancer is a safe, minimally invasive and effective treatment. -
Key words:
- Neck neoplasms /
- Iodine radioisotopes /
- Brachytherapy
-
表 1 125I粒子植入前后颈部转移瘤灶疼痛程度的变化(病灶数)
0级 1级 2级 3级 植入前 0 0 8 3 植入后 2 9 0 0 -
[1] Ragde H, Elgamal AA, Snow PB, et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer, 1998, 83(5): 989-1001. doi: 10.1002/(SICI)1097-0142(19980901)83:5<989::AID-CNCR26>3.0.CO;2-Q [2] Videtic GM, Gaspar LE, Zamorano L, et al. Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas. Int J Radiat Oncol Biol Phys, 1999, 45(3): 687-692. [3] 王洪武. 现代肿瘤靶向治疗技术. 北京: 中国医药科技出版社, 2005: 324-353.
[4] 孙燕. 癌症疼痛处理的基本原则. 中国肿瘤, 1999, 8(2): 55-56.
[5] 申文江, 王绿化, 夏延毅. 放射治疗学新技术进展. 北京: 北京科学技术出版社, 2003: 199-200.